Credits Available: 4.75 AMA PRA Category 1 Credit™ & 4.75 MOC points

Description: The goal of this initiative is to improve the care of patients with Duchenne muscular dystrophy (DMD). DMD is the most common childhood form of muscular dystrophy and characteristic manifestations are progressive muscle weakness, cardiorespiratory impairment, and premature death. Gene therapy provides a new avenue to treat life‐limiting neuromuscular disorders. Given the novelty of these therapies, clinicians involved in the care of patients with DMD may not be aware of their associated evidence and implementation. This collaborative social learning platform establishes a network of providers who can support each other locally, as well as those from different communities, with the goal of learning and sharing best practices that will improve outcomes for patients with Duchenne muscular dystrophy.

John Hopkins Medicine Logo

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse, Nurse Practitioner, Physician Assistant
Target Specialties: Pediatrics, Neurology, Orthopedic Medicine/Sports Medicine, Physiatry/Rehabilitation

Aaron Zelikovich

University of Pennsylvania
Fellow

My journey in neuromuscular disorders began in 2013 as a volunteer in the MDA Clinic at Lurie Children's in Chicago. I worked with children with Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD) as a clinical research coordinator on pivotal Phase 3 clinical trials for Spinraza, Eteplirsen, and Deflazacort.

My passion for clinical care and therapeutic development evolved as a medical student, and my focus expanded to include children and adults with neuromuscular disorders. I completed my adult neurology residency at Weill Cornell and fellowship in neuromuscular disorders at Penn.

As a practicing neurologist, I'm fortunate to help care for neuromuscular patients in New York City and the greater tri-state area. My research interests include genetic myopathies (DMD, LGMD, and more), young adults with SMA, Myasthenia Gravis, and hereditary neuropathy (hATTR, CMT). My expertise lies in clinical diagnosis, developing updated standard care guidelines, and clinical trials to improve mobility and strength in patients with neuromuscular disorders.